Catherine M. Tangen

MedicineBiochemistry, Genetics and Molecular BiologyMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.3Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genome-Wide Gene–Environment Interaction Analyses to Understand the Relationship between Red Meat and Processed Meat Intake and Colorectal Cancer Risk

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-23-0717

Top 31%

0.635DataRank

Top 31%17 citations

Joel Sanchez Mendez, Andre E. Kim, Mireia Obón‐Santacana, Ferrán Moratalla-Navarro, Vicente Martín +67 more

Papers

Driven by 76 papers — median percentile 46. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

European Urology(2023)10.1016/j.eururo.2023.08.004

N/A

2.9DataRank · unranked

93 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance +10 more

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2409

N/A

2.8DataRank · unranked

92 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia +12 more

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer

New England Journal of Medicine(2024)10.1056/nejmoa2401497

N/A

2.4DataRank · unranked

64 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

NONPARAMETRIC ANALYSIS OF COVARIANCE FOR HYPOTHESIS TESTING WITH LOGRANK AND WILCOXON SCORES AND SURVIVAL-RATE ESTIMATION IN A RANDOMIZED CLINICAL TRIAL

Journal of Biopharmaceutical Statistics(1999)10.1081/bip-100101179

N/A

2.2DataRank · unranked

42 citations

Gary G. Koch, Catherine M. Tangen

Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa154

N/A

1.6DataRank · unranked

66 citations

Ilir Agalliu, Demetrius Albanes, Kathryn Hughes Barry, Sonja I. Berndt, Qiuyin Cai +28 more

Frailty in Older Adults: Evidence for a Phenotype

The Journals of Gerontology Series A: Biological Sciences and Medical Sciences(2001)10.1093/gerona/56.3.m146

N/A

1.5DataRank · unranked

24121 citations

C. M. Tangen, J. Walston, A. B. Newman, C. Hirsch, J. Gottdiener +17 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis

EBioMedicine(2024)10.1016/j.ebiom.2024.104991

N/A

1.1DataRank · unranked

46 citations

Jamie Robinson, Daniela Mariosa, Ville Karhunen, Jian Huang, Niki Dimou +89 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4541

N/A

1.1DataRank · unranked

27 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +10 more

Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis

Nature Communications(2020)10.1038/s41467-020-14389-8

N/A

0.984DataRank · unranked

707 citations

Niki Dimou, Konstantinos K. Tsilidis, Barbara L. Banbury, Richard M Martin, Sarah J. Lewis +77 more

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Nature Genetics(2021)10.1038/s41588-020-00748-0

N/A

0.934DataRank · unranked

504 citations

Burcu F. Darst, Lilit C. Moss, Edward J. Saunders, Xin Sheng, Alisha Chou +95 more

An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk

Nature Communications(2020)10.1038/s41467-020-17673-9

N/A

0.826DataRank · unranked

246 citations

Yaohua Yang, Xingyi Guo, Xiao‐Ou Shu, Qiuyin Cai, Xiang Shu +80 more

Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study

BMC Medicine(2020)10.1186/s12916-020-01855-9

N/A

0.779DataRank · unranked

179 citations

Joshua A. Bell, Neil Murphy, Eleanor Sanderson, George Davey Smith, Nicholas J. Timpson +73 more

Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer

Prostate Cancer and Prostatic Diseases(2021)10.1038/s41391-020-00311-2

N/A

0.666DataRank · unranked

25 citations

Roshan Karunamuni, APCB BioResource (Australian Prostate Cancer BioResource), Canary PASS Investigators, Minh‐Phuong Huynh‐Le, Chun Chieh Fan +63 more

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European Urology(2023)10.1016/j.eururo.2023.06.014

N/A

0.650DataRank · unranked

20 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Genome-Wide Gene–Environment Interaction Analyses to Understand the Relationship between Red Meat and Processed Meat Intake and Colorectal Cancer Risk

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-23-0717

Top 31%

0.635DataRank

Top 31%17 citations

Joel Sanchez Mendez, Andre E. Kim, Mireia Obón‐Santacana, Ferrán Moratalla-Navarro, Vicente Martín +67 more

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

International Journal of Epidemiology(2022)10.1093/ije/dyac124

N/A

0.617DataRank · unranked

60 citations

Aurora Perez‐Cornago, Georgina K. Fensom, Karl Smith‐Byrne, Urwah Noor, Colm Andrews +66 more

Circulating adipokine concentrations and risk of five obesity‐related cancers: A Mendelian randomization study

International Journal of Cancer(2020)10.1002/ijc.33338

N/A

0.596DataRank · unranked

52 citations

Nikos Papadimitriou, Daniela Mariosa, Mattias Johansson, Paul Brennan, Ulrike Peters +17 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0.553DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

Diabetologia(2023)10.1007/s00125-023-05925-4

N/A

0.553DataRank · unranked

39 citations

Emmanouil Bouras, Andrei‐Emil Constantinescu, Kimberley Burrows, Caroline J. Bull, Emma E. Vincent +92 more

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4508

N/A

0.553DataRank · unranked

39 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3587

N/A

0.533DataRank · unranked

34 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +16 more

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.01535

N/A

0.520DataRank · unranked

31 citations

Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter J. Godolphin, Maha Hussain +15 more

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

The American Journal of Human Genetics(2023)10.1016/j.ajhg.2023.05.010

N/A

0.494DataRank · unranked

26 citations

Jiayi Shen, Ravi Madduri, Alexis Rodriguez, Yukai Xiao, Xin Sheng +95 more

The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor

Cancers(2020)10.3390/cancers12113254

N/A

0.483DataRank · unranked

24 citations

Paula Paulo, Sofia Maia, Manuela Pinheiro, Ana Peixoto, Marta Cardoso +57 more

Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study

medRxiv(2020)10.1101/2020.03.19.20031138

N/A

0.457DataRank · unranked

20 citations

Joshua A. Bell, Neil Murphy, Eleanor Sanderson, George Davey Smith, Nicholas J. Timpson +73 more

Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-21-1003

N/A

0.442DataRank · unranked

18 citations

Anna Shcherbina, Andre E. Kim, Yu‐Ru Su, Yi Lin, Jun Wang +89 more

A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk

Cancer Research(2023)10.1158/0008-5472.can-22-3713

N/A

0.434DataRank · unranked

17 citations

Andre E. Kim, Yi Lin, Conghui Qu, Marina Evangelou, Ren Yu +95 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0.434DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

Probing the diabetes and colorectal cancer relationship using gene – environment interaction analyses

British Journal of Cancer(2023)10.1038/s41416-023-02312-z

N/A

0.416DataRank · unranked

15 citations

Andre E. Kim, Orlagh Flanagan, Neil Murphy, Virginia Díez‐Obrero, Anna Shcherbina +83 more

National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network Survey of Oncology Research Professionals.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11049

N/A

0.385DataRank · unranked

12 citations

Connie M. Szczepanek, Daniel P. Petrylak, Dana B. Sparks, Catherine M. Tangen, Primo N. Lara +3 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0.360DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0.345DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial

Cancer Prevention Research(2020)10.1158/1940-6207.capr-19-0450

N/A

0.345DataRank · unranked

9 citations

İbrahim Kulaç, Berrak Gümüşkaya, Javier Baena-Del Valle, Inés Benedetti, Fan Pan +13 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0.345DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study

British Journal of Cancer(2023)10.1038/s41416-023-02489-3

N/A

0.330DataRank · unranked

8 citations

Tomas I. Gonzales, Tessa Strain, Pedro F. Saint‐Maurice, D. Timothy Bishop, Stephen J. Chanock +89 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0.330DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-22-0763

N/A

0.330DataRank · unranked

8 citations

Andre E. Kim, Yi Lin, Virginia Díez‐Obrero, Stephanie A. Bien, Conghui Qu +84 more

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5070

N/A

0.330DataRank · unranked

8 citations

Akash Roy, Siyuan S Guo, Larysa Rydzewska, Peter J. Godolphin, Maha Hussain +15 more

Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5028

N/A

0.324DataRank · unranked

4 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +11 more

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

medRxiv(2020)10.1101/2020.04.20.20072926

Top 54%

0.314DataRank

Top 54%6 citations

Minh‐Phuong Huynh‐Le, Chun Chieh Fan, Wesley Thompson, Rosalind A. Eeles, Zsofia Kote‐Jarai +41 more

S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4581

N/A

0.312DataRank · unranked

7 citations

Catherine M. Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu, Chadi Nabhan +9 more

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5001

N/A

0.312DataRank · unranked

7 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara +15 more

Characterization of Additive Gene–environment Interactions For Colorectal Cancer Risk

Epidemiology(2024)10.1097/ede.0000000000001795

Top 54%

0.306DataRank

Top 54%4 citations

Yi Lin, Michelle Kim, Eric S. Kawaguchi, Conghui Qu, Caroline Y. Um +74 more

Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis

Human Genetics and Genomics Advances(2020)10.1016/j.xhgg.2020.100010

N/A

0.269DataRank · unranked

5 citations

Xiaoliang Wang, Pierre Fontanillas, Esther Kim, Sirisak Chanprasert, Allan Gordon +55 more

Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4522

N/A

0.269DataRank · unranked

5 citations

Catherine M. Tangen, Michal Sarfaty, Ashley Marie Regazzi, I-Ling C. Lee, Woonyoung Choi +6 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5506

N/A

0.241DataRank · unranked

4 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +14 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4546

N/A

0.193DataRank · unranked

2 citations

Catherine M. Tangen, Christopher W. Ryan, Ulka N. Vaishampayan, Brian Shuch, Pedro C. Barata +7 more

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

European Urology Oncology(2024)10.1016/j.euo.2024.10.013

N/A

0.165DataRank · unranked

2 citations

Yeonjung Jo, Arshit Narang, Melissa Plets, Chadi Hage Chehade, Georges Gebrael +10 more

Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

medRxiv(2023)10.1101/2023.05.12.23289860

N/A

0.165DataRank · unranked

2 citations

Jiayi Shen, Ravi Madduri, Alexis Rodriguez, Yukai Xiao, Xin Sheng +95 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5080

N/A

0.165DataRank · unranked

2 citations

Catherine M. Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek Pinski +13 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0.165DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5071

N/A

0.165DataRank · unranked

2 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Catherine M. Tangen, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran +9 more

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

British Journal of Urology(2024)10.1111/bju.16403

N/A

0.104DataRank · unranked

1 citations

Catherine M. Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey +11 more

Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations

European Urology Focus(2025)10.1016/j.euf.2025.11.011

N/A

0DataRank · unranked

0 citations

Sam Callis, Evan Y. Yu, Scott E. Delacroix, Alexandra Sokolova, Catherine M. Tangen +4 more

Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects

Gastroenterology(2020)10.1053/j.gastro.2020.08.062

N/A

0DataRank · unranked

63 citations

Weiqiang Lin, Wanqing Wen, Jeroen R. Huyghe, Stephanie A. Bien, Qiuyin Cai +81 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5022

N/A

0DataRank · unranked

55 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +11 more

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.106

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Catherine M. Tangen, Neeraj Agarwal, Heather H. Cheng, Nicholas J. Vogelzang +5 more

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5523

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +9 more

Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial

Frontiers in Oncology(2022)10.3389/fonc.2021.808715

N/A

0DataRank · unranked

12 citations

Anna E. Płatek, Cathee Till, Phyllis J. Goodman, Catherine M. Tangen, Elizabeth A. Platz +5 more

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.536

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps591

N/A

0DataRank · unranked

1 citations

Melissa Plets, Michael A. Liss, Joshua J. Meeks, Daniel P. Petrylak, Suzanne Cole +9 more

Probing the diabetes and colorectal cancer relationship using gene – environment interaction analyses

medRxiv(2022)10.1101/2022.10.16.22280490

N/A

0DataRank · unranked

0 citations

Andre E. Kim, Orlagh Flanagan, Neil Murphy, Virginia Díez‐Obrero, Anna Shcherbina +83 more

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0602

N/A

0DataRank · unranked

19 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +12 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps581

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4608

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

Data from A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk

(2023)10.1158/0008-5472.c.6769316

N/A

0DataRank · unranked

0 citations

Andre E. Kim, Yi Lin, Conghui Qu, Marina Evangelou, Ren Yu +95 more

Data from A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk

(2023)10.1158/0008-5472.c.6769316.v1

N/A

0DataRank · unranked

0 citations

Andre E. Kim, Yi Lin, Conghui Qu, Marina Evangelou, Ren Yu +95 more

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

UNC Libraries(2023)10.17615/9cy6-py31

N/A

0DataRank · unranked

0 citations

the PRACTICAL consortium, Anders M. Dale, G. Petrovics, Thérèse Truong, Phyllis J. Goodman +42 more

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

UNC Libraries(2023)10.17615/ejg2-ya10

N/A

0DataRank · unranked

0 citations

Victoria L. Stevens, Kan Wang, Nawaid Usmani, Radka Kaneva, C.A. Haiman +73 more

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer

Nature Communications(2024)10.1038/s41467-024-52472-6

N/A

0DataRank · unranked

11 citations

Thomas Kryza, Nathalie Bock, Brian Wan-Chi Tse, Kamil A. Sokolowski, Janaththani Panchadsaram +95 more

Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial

The Journal of Urology(2024)10.1097/ju.0000000000003937

N/A

0DataRank · unranked

0 citations

Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Ian M. Thompson, Cathee Till

Catherine M. Tangen

Indexed papers

Top data-sharing exemplar

Papers